- Levine RL, Gilliland DG . Myeloproliferative disorders. Blood 2008; 112: 2190–2198.
Article CAS PubMed PubMed Central Google Scholar
- Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, Elimelech A et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008; 372: 1484–1492.
Article CAS PubMed Google Scholar
- Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005; 65: 2662–2667.
Article CAS PubMed Google Scholar
- Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, Wang D et al. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 1998; 93: 841–850.
Article CAS PubMed Google Scholar
- Hennighausen L, Robinson GW . Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. Genes Dev 2008; 22: 711–721.
Article PubMed PubMed Central Google Scholar
- Warburg O . On respiratory impairment in cancer cells. Science 1956; 124: 269–270.
CAS PubMed Google Scholar
- Pedersen PL . Tumor mitochondria and the bioenergetics of cancer cells. Prog Exp Tumor Res 1978; 22: 190–274.
Article CAS PubMed Google Scholar
- Yalcin A, Telang S, Clem B, Chesney J . Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. Exp Mol Pathol 2009; 86: 174–179.
Article CAS PubMed Google Scholar
- Van Schaftingen E, Hue L, Hers HG . Fructose 2,6-bisphosphate, the probably structure of the glucose- and glucagon-sensitive stimulator of phosphofructokinase. Biochem J 1980; 192: 897–901.
Article CAS PubMed PubMed Central Google Scholar
- Uyeda K, Furuya E, Luby LJ . The effect of natural and synthetic D-fructose 2,6-bisphosphate on the regulatory kinetic properties of liver and muscle phosphofructokinases. J Biol Chem 1981; 256: 8394–8399.
CAS PubMed Google Scholar
- Van Schaftingen E, Hers HG . Inhibition of fructose-1,6-bisphosphatase by fructose 2,6-biphosphate. Proc Natl Acad Sci USA 1981; 78: 2861–2863.
Article CAS PubMed PubMed Central Google Scholar
- Wernig G, Gonneville JR, Crowley BJ, Rodrigues MS, Reddy MM, Hudon HE et al. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood 2008; 111: 3751–3759.
Article CAS PubMed PubMed Central Google Scholar
- Reddy MM, Fernandes MS, Salgia R, Levine RL, Griffin JD, Sattler M . NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases. Leukemia 2011; 25: 281–289.
Article CAS PubMed Google Scholar
- Fernandes MS, Reddy MM, Gonneville JR, DeRoo SC, Podar K, Griffin JD et al. BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood 2009; 114: 1813–1819.
Article CAS PubMed PubMed Central Google Scholar
- Van Schaftingen E, Lederer B, Bartrons R, Hers HG . A kinetic study of pyrophosphate: fructose-6-phosphate phosphotransferase from potato tubers. Application to a microassay of fructose 2,6-bisphosphate. Eur J Biochem 1982; 129: 191–195.
Article CAS PubMed Google Scholar
- Gordan JD, Thompson CB, Simon MC . HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 2007; 12: 108–113.
Article CAS PubMed PubMed Central Google Scholar
- Dang CV, Kim JW, Gao P, Yustein J . The interplay between MYC and HIF in cancer. Nat Rev Cancer 2008; 8: 51–56.
Article CAS PubMed Google Scholar
- Clem B, Telang S, Clem A, Yalcin A, Meier J, Simmons A et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Ther 2008; 7: 110–120.
Article CAS PubMed Google Scholar
- Fatrai S, Wierenga AT, Daenen SM, Vellenga E, Schuringa JJ . Identification of HIF2alpha as an important STAT5 target gene in human hematopoietic stem cells. Blood 2011; 117: 3320–3330.
Article CAS PubMed Google Scholar
- Herrero-Mendez A, Almeida A, Fernandez E, Maestre C, Moncada S, Bolanos JP . The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C-Cdh1. Nat Cell Biol 2009; 11: 747–752.
Article CAS PubMed Google Scholar
- Bando H, Atsumi T, Nishio T, Niwa H, Mishima S, Shimizu C et al. Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer. Clin Cancer Res 2005; 11: 5784–5792.
Article CAS PubMed Google Scholar
- Kessler R, Eschrich K . Splice isoforms of ubiquitous 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in human brain. Brain Res Mol Brain Res 2001; 87: 190–195.
Article CAS PubMed Google Scholar
- Ahonen TJ, Xie J, LeBaron MJ, Zhu J, Nurmi M, Alanen K et al. Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells. J Biol Chem 2003; 278: 27287–27292.
Article CAS PubMed Google Scholar
- Lai SY, Johnson FM . Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug Resist Updat 2010; 13: 67–78.
Article CAS PubMed Google Scholar
- Clevenger CV . Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol 2004; 165: 1449–1460.
Article CAS PubMed PubMed Central Google Scholar
- Atsumi T, Chesney J, Metz C, Leng L, Donnelly S, Makita Z et al. High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res 2002; 62: 5881–5887.
CAS PubMed Google Scholar
- Kessler R, Bleichert F, Warnke JP, Eschrich K . 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) is up-regulated in high-grade astrocytomas. J Neurooncol 2008; 86: 257–264.
Article CAS PubMed Google Scholar
- Fang M, Shen Z, Huang S, Zhao L, Chen S, Mak TW et al. The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg effect, and proliferation in the PTEN pathway. Cell 2010; 143: 711–724.
Article CAS PubMed Google Scholar
- Kim JH, Chu SC, Gramlich JL, Pride YB, Babendreier E, Chauhan D et al. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood 2005; 105: 1717–1723.
Article CAS PubMed Google Scholar
- Sattler M, Verma S, Shrikhande G, Byrne CH, Pride YB, Winkler T et al. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 2000; 275: 24273–24278.
Article CAS PubMed Google Scholar
- Rodrigues MS, Reddy MM, Sattler M . Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications. Antioxid Redox Signal 2008; 10: 1813–1848.
Article CAS PubMed Google Scholar
- Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nieborowska-Skorska M et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006; 108: 319–327.
Article CAS PubMed PubMed Central Google Scholar
- Chesney J, Mitchell R, Benigni F, Bacher M, Spiegel L, Al-Abed Y et al. An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: role in tumor cell glycolysis and the Warburg effect. Proc Natl Acad Sci USA 1999; 96: 3047–3052.
Article CAS PubMed PubMed Central Google Scholar
- Chesney J, Telang S, Yalcin A, Clem A, Wallis N, Bucala R . Targeted disruption of inducible 6-phosphofructo-2-kinase results in embryonic lethality. Biochem Biophys Res Commun 2005; 331: 139–146.
Article CAS PubMed Google Scholar
- Nakajima H, Raben N, Hamaguchi T, Yamasaki T . Phosphofructokinase deficiency; past, present and future. Curr Mol Med 2002; 2: 197–212.
Article CAS PubMed Google Scholar